Editas Medicine, Inc. (EDIT)
| Market Cap | 159.89M |
| Revenue (ttm) | 35.84M |
| Net Income (ttm) | -251.23M |
| Shares Out | 83.71M |
| EPS (ttm) | -3.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,449,320 |
| Open | 1.810 |
| Previous Close | 1.800 |
| Day's Range | 1.800 - 1.970 |
| 52-Week Range | 0.910 - 6.220 |
| Beta | 2.10 |
| Analysts | Buy |
| Price Target | 6.73 (+252.36%) |
| Earnings Date | May 12, 2025 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate... [Read more]
Financial Performance
In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is $6.73, which is an increase of 252.36% from the latest price.
News
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...
Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants ...
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy...
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalass...
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice
Editas Medicine Announces First Quarter 2025 Results and Business Updates
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) a...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affir...
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today an...
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, i...
Editas Medicine Announces Chief Financial Officer Transition
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ...
Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Luce...
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentif...
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in v...
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial ...
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despi...
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burk...
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company's President and CEO Gilmore O'Neill, M.B., M....
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
On Thursday, Editas Medicine Inc. EDIT announced a strategic realignment to focus on in vivo gene editing.
Editas to reduce about 65% of its workforce over the next six months
Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies...
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced a critical pivot to optimize its cost structure, extend its ca...
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m.
Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cris...
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term.